Publications

Ung TK and Chan H-K. Effects of ramp-up of inspired airflow on in vitro aerosol dose delivery performance for certain dry powder inhalers. Eur. J. Pharm. Sci. 2016; 84: 46 – 54.

Ung TK, Rao N, Weers JG, Huang D, and Chan H-K. Design of spray dried insulin microparticles to bypass deposition in the extrathoracic region and maximize total lung delivery. Int. J. Pharm. 2016; 511: 1070 – 1079.

Weers JG, Clark AR, Rao N, Ung TK, Haynes A, Khindri SK, Sheryl A, Perry SA, Machineni S, and Colthorpe P. In vitro–in vivo correlations observed with indacaterol-based formulations delivered with the Breezhaler®. J. Aerosol Med. 2015; 28: 1 – 13.

Ung TK, Rao N, Weers JG, Clark AR, and Chan H-K. In vitro assessment of dose delivery performance of engineered dry powders for inhalation. Aerosol Sci. & Tech. 2014; 48: 1099 – 1110.

Weers JG, Ung TK, Le J, Rao N, Ament B, Axford G, Maltz D, and Chan L. Dose Emission Characteristics of Placebo PulmoSphere® Particles Are Unaffected by a Subject's Inhalation Maneuver. J. Aerosol Med. 2013; 26: 56 – 68.

Ung TK, Axford G, Chan L, Glusker M, Le J, Maltz D, Rao N, and Weers JG. Effect of powder release kinetics on the performance of a dry powder inhaler. Resp. Drug Delivery. 2012; 3: 627 – 630.

Weers JG, Maltz DS, Ung TK, Chan L, Glusker M, Ament B, Le J, Rao N, and Axford G. Minimizing Human Factors Effects through Inhaler Design. Resp. Drug Delivery. 2012; pp. 217 – 226.

Pritchard JN, Elphick M, Hollen D von, Nikander K, Hardaker LEA, Hatley RHM (2015) Factors to consider when selecting a nebulizer for new inhaled product development. Expert Opinion. Drug Delivery. Vol. 12, No. 8: 1375-1387

Pritchard JN (2015) Industry guidance for the selection of a delivery system for the development of novel respiratory products. Expert Opinion. Drug Delivery. 12(11): 1755-1765.

Pritchard JN (2017) Overlooked opportunities for nebulizers in inhalation product development. Inhalation 11(3): 9-17

Pritchard JN, Hatley RHM, Denyer J, Hollen D von (2018) Mesh nebulizers have become the first choice for new nebulized pharmaceutical drug developments Ther. Del. 9(2): 121-136

Elphick M, Hollen D von, Pritchard JN, Nikander K, Hardaker L, Hatley RHM (2015) Factors to consider when selecting a nebulizer for new inhaled product development. Expert Opinion. Drug Delivery. Vol. 12, No. 8: 1375-1387

Pritchard JN, Giles R (2014) Opportunities in respiratory drug delivery. Ther. Deliv. 5(12):1261-73

Nikander K, Nicholls C, Denyer J, Pritchard JN (2014) The Evolution of Spacers and Valved Holding Chambers J. Aerosol Medicine. Pulm. Drug Delivery. 27(S1): S4-S23

Pritchard JN (2001): The influence of lung deposition on clinical response. J. Aerosol Med. 14 Suppl 1:S19-26.

Zeng XM, Martin GP, Marriott C, Pritchard JN (2001) Lactose as a carrier in dry powder formulations: the influence of surface characteristics on drug delivery. J Pharm. Sci.; 90(9):1424-34.

Larhrib H, Zeng XM, Martin GP, Marriott C, Pritchard JN (1999): The use of different grades of lactose as a carrier for aerosolised salbutamol sulphate.. Int. J. Pharmaceut. 191(1):1-14.

Pritchard JN (2020) F-Gas Regulations and Beyond: Clinical and Economic Factors that will Drive Propellant Transition. Respiratory Drug Delivery 2020, Dalby RN, Byron PR, Peart J et al (Eds)., Vol. 1: 183-193. Virginia Commonwealth University, VA, USA

Hatley RHM, Parker J, Slator L, Hardaker L, Toomer M, Pritchard JN (2018) Dose Inconsistency Through Pressurized Metered Dose Inhaler Canister Life. Respiratory Drug Delivery 2018. Volume 2, 2018: 485-490.

Pritchard JN, Potter R, Hatley RHM (2018) Dose Consistency from a Mesh Nebulizer Over a Range of Peak Inhalation Flow Rates. Respiratory Drug Delivery 2018. Volume 2, 2018: 491-496.

Pritchard JN (2016) Back to the Future with Nebulized Therapy: New Opportunities in a Growing Market Respiratory Drug Delivery Asia, Dalby RN, Peart J, Young PM, Traini D (Eds)., Vol. 1: 15-24. Virginia Commonwealth University, VA, USA

Hatley R, Hardaker L, Zarins-Tutt J, Quadrelli F, Hogan B, MacLoughlan R, Pritchard JN (2016). Investigation of Optical Density for the Characterization of Nebulizer Meshes. Pp 489-492 in Respiratory Drug Delivery 2016, Volume 3, Edited by Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM, Traini D. DHI Publishing; River Grove, IL

Hatley RHM, Potter R, Hardaker L, Metcalf A, Pritchard JN (2016) Investigation of Potential Secondary Aerosol Exposure during Aerosolization from an Aeroneb(R) Go(tm) Nebulizer pp 493-496 in Respiratory Drug Delivery 2016, Volume 3, Edited by Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM, Traini D. DHI Publishing; River Grove, IL

Pritchard JN (2016) Maximizing the Effectiveness of the Inhaled Drug Development Process. Pp 497-502 in Respiratory Drug Delivery 2016, Volume 3, Edited by Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM, Traini D. DHI Publishing; River Grove, IL

Zijlstra E, Moerschel LP, Ermer M, Klein O, Porter L, Bueche B, Kuo M, Le T, Stedman BJ and PATTON JS. 1085-P: Dance 501 Inhaled Human Insulin (INH): Linear Dose Response, Earlier Onset of Action, and Higher Early Effect than s.c. Insulin Lispro (LIS). Diabetes 2019 Jun; 68(Supplement 1)

Fink JB, Molloy L, Patton JS, et al. Good Things in Small Packages: an Innovative Delivery Approach for Inhaled Insulin. Pharm Res 34, 2568–2578 (2017).

Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov 6, 67–74 (2007).

Patton JS. Mechanisms of macromolecule absorption by the lungs, Advanced Drug Delivery Reviews, Volume 19, Issue 1,1996, 3-36, ISSN 0169-409X

Patton JS, Fishburn SC, and Weers JG. : The Lungs as a Portal of Entry for Systemic Drug Delivery. Proc Am Thorac Soc Vol 1. pp 338–344, 2004

Patton JS, Bukar J, Nagarajan S. Inhaled Insulin1 Advanced Drug Delivery Reviews, Vol 35, 2–3, 1 Feb1999, 235-247

Patton JS, Platz R. (D) Routes of delivery: Case studies: (2) Pulmonary delivery of peptides and proteins for systemic action. Advanced Drug Delivery Reviews Volume 8, 2–3, March–June 1992, 179-196

Byron P, Patton JS. Drug Delivery via the Respiratory Tract. Journal of Aerosol Medicine. Jan 1994.49-75. Volume: 7 Issue 1: March 19, 2009

Patton JS, Bukar J, & Eldon M, Clinical Pharmacokinetics and Pharmacodynamics of Inhaled Insulin. Clin Pharmacokinet 43, 781–801 (2004).

Patton JS, Brain JD, Davies LS, Fiegel J, Gumbleton M, Kim KJ, Sakagami M, Vanbever R, and Ehrhardt C. The Particle has Landed—Characterizing the Fate of Inhaled Pharmaceuticals. Journal of Aerosol Medicine and Pulmonary Drug Delivery. Dec 2010.S-71-S-87.

Patton JS Practical Considerations for Drug Delivery to the Respiratory Tract Nanoparticles in the Lung: Environmental Exposure and Drug Delivery. Chapter 13, Akira Tsuda, Peter Gehr CRC Press, Dec 19, 2014

Patton JS, McCabe JG, Hansen SE, and Daugherty AL. Pharmacology Department, Genentech, Inc. Absorption of Human Growth Hormone From the Rat Lung. Biotechnology Therapeutics, 1(3), 213w228 (1989—1990)